- Home
- PBT vs ERAS Comparison
PBT vs ERAS Comparison
Compare PBT & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBT
- ERAS
- Stock Information
- Founded
- PBT 1980
- ERAS 2018
- Country
- PBT United States
- ERAS United States
- Employees
- PBT N/A
- ERAS N/A
- Industry
- PBT Oil & Gas Production
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- PBT Energy
- ERAS Health Care
- Exchange
- PBT Nasdaq
- ERAS Nasdaq
- Market Cap
- PBT 475.4M
- ERAS 410.8M
- IPO Year
- PBT N/A
- ERAS 2021
- Fundamental
- Price
- PBT $10.52
- ERAS $1.33
- Analyst Decision
- PBT
- ERAS Strong Buy
- Analyst Count
- PBT 0
- ERAS 6
- Target Price
- PBT N/A
- ERAS $4.83
- AVG Volume (30 Days)
- PBT 81.2K
- ERAS 1.3M
- Earning Date
- PBT 01-01-0001
- ERAS 05-20-2025
- Dividend Yield
- PBT 3.94%
- ERAS N/A
- EPS Growth
- PBT N/A
- ERAS N/A
- EPS
- PBT 0.55
- ERAS N/A
- Revenue
- PBT $27,114,144.00
- ERAS N/A
- Revenue This Year
- PBT N/A
- ERAS N/A
- Revenue Next Year
- PBT N/A
- ERAS N/A
- P/E Ratio
- PBT $18.56
- ERAS N/A
- Revenue Growth
- PBT N/A
- ERAS N/A
- 52 Week Low
- PBT $8.01
- ERAS $1.01
- 52 Week High
- PBT $14.26
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- PBT 62.56
- ERAS 48.02
- Support Level
- PBT $9.73
- ERAS $1.37
- Resistance Level
- PBT $10.20
- ERAS $1.53
- Average True Range (ATR)
- PBT 0.34
- ERAS 0.13
- MACD
- PBT 0.07
- ERAS -0.00
- Stochastic Oscillator
- PBT 97.37
- ERAS 30.86
About PBT Permian Basin Royalty Trust
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole and others across Texas. The company earns majority revenue in form of royalties received through its properties.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.